Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
NEW YORK (Reuters Health) – In patients with untreated advanced non-small-cell lung cancer (NSCLC), adding cetuximab (Erbitux) to platinum-based chemotherapy can improve overall survival and response rates, a…
NEW YORK (Reuters Health) – The risk of hip fracture is significantly lower when organic nitrates are used as needed rather than continuously, according to a February 3rd…
NEW YORK (Reuters Health) – In patients with psoriatic arthritis, once weekly etanercept (Enbrel) is suitable for joint symptoms but twice weekly dosing is needed to best address…
NEW YORK (Reuters Health) – Use of paroxetine during tamoxifen therapy reduces the breast cancer survival benefit by 25% or more depending on the amount of time the…
NEW YORK (Reuters Health) – With intensive medical therapy, fewer than 5% of patients with asymptomatic carotid stenosis will gain additional benefit from revascularization, according to a report…
NEW YORK (Reuters Health) – Type 2 diabetics treated with rosiglitazone are at increased risk of heart failure events, researchers report in the January 29th online issue of…
NEW YORK (Reuters Health) – Patients with Huntington’s disease treated with the investigational drug latrepirdine (dimebon) showed signs of improved cognitive function in a 3-month trial, investigators report.…
NEW YORK (Reuters Health) – Triple antiplatelet therapy is more effective than dual therapy at reducing ischemic events after implantation of a drug-eluting stent (DES), according to an…
NEW YORK (Reuters Health) – Potassium monitoring can help prevent drug-associated hyperkalemia events in patients with diabetes, according to a report in the January 20th online issue of…
NEW YORK (Reuters Health) – For acute gout flare, a 1-hour low-dose oral colchicine regimen offers comparable efficacy and better tolerability than the more common 6-hour high-dose regimen,…
